Skip to main content
NCBI home page
Journal of Medical Genetics logoLink to Journal of Medical Genetics
. 1999 Aug;36(8):610–614.

Mutational analysis of the N-ras, p53, p16INK4a, CDK4, and MC1R genes in human congenital melanocytic naevi

T Papp 1, H Pemsel 1, R Zimmermann 1, R Bastrop 1, D Weiss 1, D Schiffmann 1
PMCID: PMC1762982  PMID: 10465111

Abstract

Eighteen human congenital melanocytic naevi (CMN) from 17 patients were screened for activating point mutations in the oncogenes N-ras and CDK4 and for sequence variants in the MC1R gene by combined RFLP-PCR/SSCP analysis. In addition, all lesions were screened for deletions and point mutations in the tumour suppressor genes p53 and p16INK4a (CDKN2A) by combined multiplex PCR/SSCP analysis. Positive screening data were specified by sequencing of the corresponding PCR product. Activating point mutations in the N-ras gene (nine CAA (Gln) to AAA (Lys) transversions and one CAA (Gln) to CGA (Arg) transition at codon 61) were detected at high frequency (56%). Furthermore, three missense mutations (V92M) and two silent mutations (CGA (Arg) to CGG (Arg), codon 213, exon 6) were found in the MC1R and p53 genes, respectively. No mutations were found in p16 or CDK4. The activated N-ras oncogene, which is also found in human cutaneous melanomas, may constitute a potential risk factor for melanoma formation within CMN.


Keywords: naevi; N-ras; p53; p16

Full Text

The Full Text of this article is available as a PDF (101.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Albino A. P., Nanus D. M., Mentle I. R., Cordon-Cardo C., McNutt N. S., Bressler J., Andreeff M. Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype. Oncogene. 1989 Nov;4(11):1363–1374. [PubMed] [Google Scholar]
  2. Ballmaier D., Pflaum M., Kielbassa C., Epc B. Oxidative DNA damage profiles in mammalian cells. Recent Results Cancer Res. 1997;143:35–47. doi: 10.1007/978-3-642-60393-8_3. [DOI] [PubMed] [Google Scholar]
  3. Bliss J. M., Ford D., Swerdlow A. J., Armstrong B. K., Cristofolini M., Elwood J. M., Green A., Holly E. A., Mack T., MacKie R. M. Risk of cutaneous melanoma associated with pigmentation characteristics and freckling: systematic overview of 10 case-control studies. The International Melanoma Analysis Group (IMAGE). Int J Cancer. 1995 Aug 9;62(4):367–376. doi: 10.1002/ijc.2910620402. [DOI] [PubMed] [Google Scholar]
  4. Cairns P., Polascik T. J., Eby Y., Tokino K., Califano J., Merlo A., Mao L., Herath J., Jenkins R., Westra W. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet. 1995 Oct;11(2):210–212. doi: 10.1038/ng1095-210. [DOI] [PubMed] [Google Scholar]
  5. Caldas C., Hahn S. A., da Costa L. T., Redston M. S., Schutte M., Seymour A. B., Weinstein C. L., Hruban R. H., Yeo C. J., Kern S. E. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet. 1994 Sep;8(1):27–32. doi: 10.1038/ng0994-27. [DOI] [PubMed] [Google Scholar]
  6. Carr J., Mackie R. M. Point mutations in the N-ras oncogene in malignant melanoma and congenital naevi. Br J Dermatol. 1994 Jul;131(1):72–77. doi: 10.1111/j.1365-2133.1994.tb08460.x. [DOI] [PubMed] [Google Scholar]
  7. Elwood J. M. Melanoma and sun exposure: contrasts between intermittent and chronic exposure. World J Surg. 1992 Mar-Apr;16(2):157–165. doi: 10.1007/BF02071515. [DOI] [PubMed] [Google Scholar]
  8. Epe B. DNA damage profiles induced by oxidizing agents. Rev Physiol Biochem Pharmacol. 1996;127:223–249. doi: 10.1007/BFb0048268. [DOI] [PubMed] [Google Scholar]
  9. Gruis N. A., Weaver-Feldhaus J., Liu Q., Frye C., Eeles R., Orlow I., Lacombe L., Ponce-Castaneda V., Lianes P., Latres E. Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression. Am J Pathol. 1995 May;146(5):1199–1206. [PMC free article] [PubMed] [Google Scholar]
  10. Guldberg P., Kirkin A. F., Gronbaek K., thor Straten P., Ahrenkiel V., Zeuthen J. Complete scanning of the CDK4 gene by denaturing gradient gel electrophoresis: a novel missense mutation but low overall frequency of mutations in sporadic metastatic malignant melanoma. Int J Cancer. 1997 Sep 4;72(5):780–783. doi: 10.1002/(sici)1097-0215(19970904)72:5<780::aid-ijc13>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  11. Hahn S. A., Kern S. E. Molecular genetics of exocrine pancreatic neoplasms. Surg Clin North Am. 1995 Oct;75(5):857–869. doi: 10.1016/s0039-6109(16)46732-0. [DOI] [PubMed] [Google Scholar]
  12. Haluska F. G., Hodi F. S. Molecular genetics of familial cutaneous melanoma. J Clin Oncol. 1998 Feb;16(2):670–682. doi: 10.1200/JCO.1998.16.2.670. [DOI] [PubMed] [Google Scholar]
  13. Harsanyi Z. P., Post P. W., Brinkmann J. P., Chedekel M. R., Deibel R. M. Mutagenicity of melanin from human red hair. Experientia. 1980 Mar 15;36(3):291–292. doi: 10.1007/BF01952282. [DOI] [PubMed] [Google Scholar]
  14. Hollstein M., Rice K., Greenblatt M. S., Soussi T., Fuchs R., Sørlie T., Hovig E., Smith-Sørensen B., Montesano R., Harris C. C. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res. 1994 Sep;22(17):3551–3555. [PMC free article] [PubMed] [Google Scholar]
  15. Hollstein M., Sidransky D., Vogelstein B., Harris C. C. p53 mutations in human cancers. Science. 1991 Jul 5;253(5015):49–53. doi: 10.1126/science.1905840. [DOI] [PubMed] [Google Scholar]
  16. Holly E. A., Aston D. A., Cress R. D., Ahn D. K., Kristiansen J. J. Cutaneous melanoma in women. II. Phenotypic characteristics and other host-related factors. Am J Epidemiol. 1995 May 15;141(10):934–942. doi: 10.1093/oxfordjournals.aje.a117360. [DOI] [PubMed] [Google Scholar]
  17. Jafari M., Papp T., Kirchner S., Diener U., Henschler D., Burg G., Schiffmann D. Analysis of ras mutations in human melanocytic lesions: activation of the ras gene seems to be associated with the nodular type of human malignant melanoma. J Cancer Res Clin Oncol. 1995;121(1):23–30. doi: 10.1007/BF01202725. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Jimbow K. Current update and trends in melanin pigmentation and melanin biology. Keio J Med. 1995 Mar;44(1):9–18. doi: 10.2302/kjm.44.9. [DOI] [PubMed] [Google Scholar]
  19. Jimbow K., Ishida O., Ito S., Hori Y., Witkop C. J., Jr, King R. A. Combined chemical and electron microscopic studies of pheomelanosomes in human red hair. J Invest Dermatol. 1983 Dec;81(6):506–511. doi: 10.1111/1523-1747.ep12522838. [DOI] [PubMed] [Google Scholar]
  20. Kamb A., Gruis N. A., Weaver-Feldhaus J., Liu Q., Harshman K., Tavtigian S. V., Stockert E., Day R. S., 3rd, Johnson B. E., Skolnick M. H. A cell cycle regulator potentially involved in genesis of many tumor types. Science. 1994 Apr 15;264(5157):436–440. doi: 10.1126/science.8153634. [DOI] [PubMed] [Google Scholar]
  21. Kastan M. B., Onyekwere O., Sidransky D., Vogelstein B., Craig R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 1991 Dec 1;51(23 Pt 1):6304–6311. [PubMed] [Google Scholar]
  22. Koppula S. V., Robbins L. S., Lu D., Baack E., White C. R., Jr, Swanson N. A., Cone R. D. Identification of common polymorphisms in the coding sequence of the human MSH receptor (MCIR) with possible biological effects. Hum Mutat. 1997;9(1):30–36. doi: 10.1002/(SICI)1098-1004(1997)9:1<30::AID-HUMU5>3.0.CO;2-T. [DOI] [PubMed] [Google Scholar]
  23. Lane D. P. Cancer. p53, guardian of the genome. Nature. 1992 Jul 2;358(6381):15–16. doi: 10.1038/358015a0. [DOI] [PubMed] [Google Scholar]
  24. Lee J. Y., Dong S. M., Shin M. S., Kim S. Y., Lee S. H., Kang S. J., Lee J. D., Kim C. S., Kim S. H., Yoo N. J. Genetic alterations of p16INK4a and p53 genes in sporadic dysplastic nevus. Biochem Biophys Res Commun. 1997 Aug 28;237(3):667–672. doi: 10.1006/bbrc.1997.7212. [DOI] [PubMed] [Google Scholar]
  25. Moriya M., Ou C., Bodepudi V., Johnson F., Takeshita M., Grollman A. P. Site-specific mutagenesis using a gapped duplex vector: a study of translesion synthesis past 8-oxodeoxyguanosine in E. coli. Mutat Res. 1991 May;254(3):281–288. doi: 10.1016/0921-8777(91)90067-y. [DOI] [PubMed] [Google Scholar]
  26. Moriya M. Single-stranded shuttle phagemid for mutagenesis studies in mammalian cells: 8-oxoguanine in DNA induces targeted G.C-->T.A transversions in simian kidney cells. Proc Natl Acad Sci U S A. 1993 Feb 1;90(3):1122–1126. doi: 10.1073/pnas.90.3.1122. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Nigro J. M., Baker S. J., Preisinger A. C., Jessup J. M., Hostetter R., Cleary K., Bigner S. H., Davidson N., Baylin S., Devilee P. Mutations in the p53 gene occur in diverse human tumour types. Nature. 1989 Dec 7;342(6250):705–708. doi: 10.1038/342705a0. [DOI] [PubMed] [Google Scholar]
  28. Papp T., Jafari M., Schiffmann D. Lack of p53 mutations and loss of heterozygosity in non-cultured human melanocytic lesions. J Cancer Res Clin Oncol. 1996;122(9):541–548. doi: 10.1007/BF01213550. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Ranadive N. S., Shirwadkar S., Persad S., Menon I. A. Effects of melanin-induced free radicals on the isolated rat peritoneal mast cells. J Invest Dermatol. 1986 Mar;86(3):303–307. doi: 10.1111/1523-1747.ep12285496. [DOI] [PubMed] [Google Scholar]
  30. Reed J. A., Loganzo F., Jr, Shea C. R., Walker G. J., Flores J. F., Glendening J. M., Bogdany J. K., Shiel M. J., Haluska F. G., Fountain J. W. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res. 1995 Jul 1;55(13):2713–2718. [PubMed] [Google Scholar]
  31. Schleicher S. M., Lim S. J. Congenital nevi. Int J Dermatol. 1995 Dec;34(12):825–829. doi: 10.1111/j.1365-4362.1995.tb04414.x. [DOI] [PubMed] [Google Scholar]
  32. Shibutani S., Takeshita M., Grollman A. P. Insertion of specific bases during DNA synthesis past the oxidation-damaged base 8-oxodG. Nature. 1991 Jan 31;349(6308):431–434. doi: 10.1038/349431a0. [DOI] [PubMed] [Google Scholar]
  33. Sober A. J., Burstein J. M. Precursors to skin cancer. Cancer. 1995 Jan 15;75(2 Suppl):645–650. doi: 10.1002/1097-0142(19950115)75:2+<645::aid-cncr2820751405>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  34. Soussi T., Caron de Fromentel C., May P. Structural aspects of the p53 protein in relation to gene evolution. Oncogene. 1990 Jul;5(7):945–952. [PubMed] [Google Scholar]
  35. Soussi T., Caron de Fromentel C., Méchali M., May P., Kress M. Cloning and characterization of a cDNA from Xenopus laevis coding for a protein homologous to human and murine p53. Oncogene. 1987 Mar;1(1):71–78. [PubMed] [Google Scholar]
  36. Thody A. J., Higgins E. M., Wakamatsu K., Ito S., Burchill S. A., Marks J. M. Pheomelanin as well as eumelanin is present in human epidermis. J Invest Dermatol. 1991 Aug;97(2):340–344. doi: 10.1111/1523-1747.ep12480680. [DOI] [PubMed] [Google Scholar]
  37. Tsao H., Benoit E., Sober A. J., Thiele C., Haluska F. G. Novel mutations in the p16/CDKN2A binding region of the cyclin-dependent kinase-4 gene. Cancer Res. 1998 Jan 1;58(1):109–113. [PubMed] [Google Scholar]
  38. Tsao H., Sober A. J. Ultraviolet radiation and malignant melanoma. Clin Dermatol. 1998 Jan-Feb;16(1):67–73. doi: 10.1016/s0738-081x(97)00191-0. [DOI] [PubMed] [Google Scholar]
  39. Valverde P., Healy E., Jackson I., Rees J. L., Thody A. J. Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans. Nat Genet. 1995 Nov;11(3):328–330. doi: 10.1038/ng1195-328. [DOI] [PubMed] [Google Scholar]
  40. Valverde P., Healy E., Sikkink S., Haldane F., Thody A. J., Carothers A., Jackson I. J., Rees J. L. The Asp84Glu variant of the melanocortin 1 receptor (MC1R) is associated with melanoma. Hum Mol Genet. 1996 Oct;5(10):1663–1666. doi: 10.1093/hmg/5.10.1663. [DOI] [PubMed] [Google Scholar]
  41. Velculescu V. E., El-Deiry W. S. Biological and clinical importance of the p53 tumor suppressor gene. Clin Chem. 1996 Jun;42(6 Pt 1):858–868. [PubMed] [Google Scholar]
  42. Wölfel T., Hauer M., Schneider J., Serrano M., Wölfel C., Klehmann-Hieb E., De Plaen E., Hankeln T., Meyer zum Büschenfelde K. H., Beach D. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science. 1995 Sep 1;269(5228):1281–1284. doi: 10.1126/science.7652577. [DOI] [PubMed] [Google Scholar]
  43. Xu X., Thörnwall M., Lundin L. G., Chhajlani V. Val92Met variant of the melanocyte stimulating hormone receptor gene. Nat Genet. 1996 Dec;14(4):384–384. doi: 10.1038/ng1296-384. [DOI] [PubMed] [Google Scholar]
  44. van Elsas A., Zerp S. F., van der Flier S., Krüse K. M., Aarnoudse C., Hayward N. K., Ruiter D. J., Schrier P. I. Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma. Am J Pathol. 1996 Sep;149(3):883–893. [PMC free article] [PubMed] [Google Scholar]
  45. van Elsas A., Zerp S. F., van der Flier S., Krüse K. M., Aarnoudse C., Hayward N. K., Ruiter D. J., Schrier P. I. Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma. Am J Pathol. 1996 Sep;149(3):883–893. [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Medical Genetics are provided here courtesy of BMJ Publishing Group

RESOURCES